Learn more

SYNTHON BV

Overview
  • Total Patents
    832
  • GoodIP Patent Rank
    8,889
  • Filing trend
    ⇧ 21.0%
About

SYNTHON BV has a total of 832 patent applications. It increased the IP activity by 21.0%. Its first patent ever was published in 1997. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are HUAIAN ANLAI BIOTECHNOLOGY CO LTD, ARATANA THERAPEUTICS NV and KRKA TOVARNA ZDRAVIL D D NOVO.

Patent filings per year

Chart showing SYNTHON BVs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Picha Frantisek 109
#2 Peters Theodorus Hendricus Ant 98
#3 Lemmens Jacobus Maria 97
#4 Zhu Jie 57
#5 Keltjens Rolf 55
#6 Platteeuw Johannes Jan 50
#7 Van Dalen Frans 49
#8 Alvarez Fernandez Lisardo 43
#9 Thijs Lambertus 41
#10 Overeem Arjanne 40

Latest patents

Publication Filing date Title
WO2021064166A1 Crystalline forms of bempedoic acid
WO2021064123A1 Pharmaceutical composition comprising enzalutamide
WO2021053175A1 Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 Salts of omecamtiv mecarbil and solid forms thereof
WO2021038014A1 Controlled release tofacitinib compositions
WO2021037597A1 Isavuconazonium salts and process for preparing thereof
WO2021009306A1 Improved process for preparing ozanimod
WO2020260469A1 Process for preparation of enzalutamide
WO2020234423A1 Siponimod maleic acid and fumaric acid salt
WO2020225413A1 Pharmaceutical composition comprising axitinib
WO2020212253A1 Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
WO2020208167A1 Solid forms of siponimod
WO2020201172A1 Process for making siponimod and intermediate thereof
WO2020115200A1 Improved process for preparing ozanimod
AU2019352722A1 Crystalline forms and processes of lenvatinib besylate
EP3802529A1 A process for making palbociclib
WO2019224058A1 Controlled release tofacitinib compositions
WO2020216450A1 Pharmaceutical composition comprising amorphous sunitinib
EP3775026A1 Purification of sugammadex
US2021038525A1 Tablet compositions comprising abiraterone acetate